Applied Filters
Formal obligations: burdens on biotech patents
The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important.
A brave new world for supplementary protection certificates?
Advocate-General Verica Trstenjak has delivered an opinion in the case of Neurim Pharmaceuticals that, if followed by the Court of Justice of the EU, will profoundly liberalise the law governing SPCs in Europe.
Life sciences in Europe: the key jurisdictions
The European life sciences industry has a long history. Many of the major players trace their roots to before the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions.
It’s good to litigate a patent or two
Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled.
Clinical trials and stratified medicine—maximising patent exclusivity
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs.
The role of the function of DNA sequence before and after grant
Recent European decisions have provided much to think about for practitioners concerned with DNA sequences. Caroline Pallard and Bart Swinkels investigate.
Patentability of dosage regimens in Europe
First instance courts in France have adopted controversial interpretations of an important Enlarged Board of Appeal decision, says Stéphane Agasse.
Windows of opportunity and closing doors at the EPO
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions.
Patenting life
A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains.
What next for stem cell research?
The European Court of Justice is faced with a crucial decision on stem cell research. Justin Turner QC explains.
